Vericel Co. (NASDAQ:VCEL) Shares Sold by Fmr LLC

Fmr LLC cut its position in shares of Vericel Co. (NASDAQ:VCEL) by 10.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,134,975 shares of the biotechnology company’s stock after selling 237,837 shares during the period. Fmr LLC owned 4.33% of Vericel worth $117,231,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI acquired a new position in shares of Vericel during the fourth quarter valued at approximately $48,000. Smartleaf Asset Management LLC lifted its stake in Vericel by 511.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 1,058 shares in the last quarter. Meeder Asset Management Inc. grew its position in shares of Vericel by 8.4% in the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 183 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,240 shares during the last quarter. Finally, KBC Group NV lifted its position in Vericel by 82.5% during the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,224 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Truist Financial cut their target price on Vericel from $61.00 to $51.00 and set a “buy” rating for the company in a research note on Friday. Canaccord Genuity Group lifted their target price on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Stephens reissued an “overweight” rating and issued a $65.00 price target on shares of Vericel in a research note on Wednesday, January 15th. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Vericel has an average rating of “Moderate Buy” and an average price target of $60.86.

Insider Transactions at Vericel

In other news, CEO Dominick Colangelo sold 26,592 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total value of $1,217,381.76. Following the sale, the chief executive officer now directly owns 259,997 shares in the company, valued at approximately $11,902,662.66. This trade represents a 9.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Siegal sold 3,908 shares of Vericel stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the completion of the transaction, the insider now owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. This trade represents a 76.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,942 shares of company stock valued at $2,724,548. 5.20% of the stock is currently owned by corporate insiders.

Vericel Price Performance

Shares of Vericel stock opened at $41.23 on Tuesday. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of 687.28 and a beta of 1.61. The business has a 50-day moving average of $48.80 and a 200 day moving average of $51.46. Vericel Co. has a 12 month low of $37.76 and a 12 month high of $63.00.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.